Krystal Biotech, Inc.

NASDAQ:KRYS

Biotechnology

Healthcare
$315.34 +5.66%

+$18.29 today

Market cap
$9.34B
Beta
0.53
P/E (TTM)
44.5
EPS (TTM)
$7.68
52W Low $130.17High $347.67

Volume 0.35M

Average 0.29M

KRYS Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Krystal Biotech, Inc.NASDAQ: KRYS

Net Debt · Q2 FY2026 · quarter ended Jun 2026

Net debt remains negative

Q2 FY2026 net debt was -$418.89M, compared with -$344.15M a year earlier.

Context

  • Net debt amounted to 27.9% of total assets at the end of Q2 FY2026, down 2.3 pp from a year earlier.
  • Net debt grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -21.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$418.89M+14.9% QoQ
Last fiscal yearDec 2025
-$486.97M-44.2% YoY
Year agoJun 2025
-$344.15M-21.7% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.7%——
1 year-44.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(486.97M) USD
Year-over-year change
-44.2%

Net Debt vs competitors

How KRYS compares with its peers on the latest reported figures

  • KRYS's Jun 2026 net debt of -$418.89M is the lowest of the 6 companies compared; the peer median is -$8.47M.
  • Its year-over-year change of -21.7% is the 4th highest of 6, against a peer median of -1.6%.
  • Net debt amounts to 27.9% of total assets for KRYS, versus a peer median of 8.7%.
KRYS Competitors Peer median
Net Debt for KRYS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RGNXREGENXBIO Inc.Mar 2026$55.84M +211.1%—16.3%
MGTXMeiraGTx Holdings plcMar 2026$15.99M +11.4%—6.5%
SANASana Biotechnology, Inc.Mar 2026-$8.47M -75.9%—2.3%
RCKTRocket Pharmaceuticals, Inc.Mar 2026-$24.85M -1.6%—8.7%
ABEOAbeona Therapeutics Inc.Mar 2026-$38.2M -575.1%—19.2%
KRYSKrystal Biotech, Inc.Jun 2026-$418.89M -21.7%—27.9%
Peer median (excluding KRYS) -$8.47M-1.6%—8.7%

Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents341.25M161.9M358.33M344.87M496.3M
Short-term Investments96.85M217.27M173.85M252.65M331.49M
Net Receivables0042.04M104.75M127.43M
Inventory006.99M26.51M40.48M
Other Current Assets04.61M6.71M13.27M28.91M
Total Current Assets442.27M383.78M587.91M742.05M1.02B
Property, Plant & Equipment (Net)119.58M169.73M168.23M161.45M158.02M
Goodwill00000
Intangible Assets00000
Long-term Investments64.37M4.62M61.95M152.11M128.07M
Tax Assets000022.82M
Other Non-current Assets74K324K263K231K287K
Total Non-current Assets184.03M174.67M230.45M313.79M309.19M
Total Assets626.3M558.45M818.36M1.06B1.33B
Account Payables8.4M3.98M1.85M4.99M3.24M
Short-term Debt00000
Tax Payables83K43K2.28M4.29M0
Deferred Revenue00000
Other Current Liabilities87K267K16.75M2.4M3.58M
Total Current Liabilities25.74M28.85M33.09M102M102.94M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0001.42M3.72M
Total Non-current Liabilities6.98M7.37M6.62M7.46M11.29M
Total Liabilities32.72M36.22M39.71M109.46M114.23M
Common Stock00000
Retained Earnings(140.78M)(280.76M)(269.83M)(180.67M)24.16M
Accumulated OCI(163K)(728K)638K(190K)1.14M
Other Stockholders Equity00000
Minority Interest00000
Total Equity593.58M522.23M778.64M946.38M1.22B
Total Debt8.02M8.93M8.09M7.26M9.34M
Net Debt(333.22M)(152.97M)(350.23M)(337.6M)(486.97M)

Krystal Biotech, Inc.

NASDAQ:KRYS

Intrinsic Alpha fair value

Locked

Current Price

$315.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.